Skip to Content
Search Menu

EHA23 – Novel CAR Therapy for AML Shows Favorable Pre-Clinical Outcomes

A novel combinatorial CAR therapy ADCLEC.syn1, designed to co-target ADGRE2 and CLEC12A for selective elimination of AML, shows exciting results.

Get access

If you are a doctor or other health professional, you can access the entire article by creating a profile on BestPractice Nordic.

Relateret indhold

Nordic AML Insights: Research and Ph.D. Contributions

/ Jan Andreasen
AML

AML Insights: What’s New in the Field

/ Jan Andreasen
AML
Michael Savona

AML: Oral Decitabine–Cedazuridine Is Equivalent to Intravenous Decitabine

/ Michael Savona
AMLLeukemia Play the Video 08:00

Liposomal Daunorubicin + Cytarabine: Enhanced Synergistic Antineoplastic Effect in AML Treatment

/ Andrea Lenartova / Jan Andreasen
AML
Fabian Müller

Treatment of Autoimmune Patients with CD19-CAR T Cells Results in Long-Term Drug-Free Remission or No Progression

/ Fabian Mueller
ASH24CAR-T Play the Video 03:36
Gunnar Juliusson

Swedish Result for Cytarabine Treatment of Secondary AML is Better than the Register Studies

/ Gunnar Juliusson
AML Play the Video 07:05
Hanna Duàn

Genomic Subtypes of AML Determines Sensitivity to NK Cell Cytotoxicity

/ Hanna Duàn
AMLASH24 Play the Video 2:36
Gunnar Juliusson

Cytarabine Dose Intensification Improves Survival in Older Patients with AML

/ Gunnar Juliusson
AML Play the Video 08:21

The Development of New Treatment Options within AML Is Slower Than in Other Disease Areas within Hematology

/ BestPractice Nordic
AMLEHA24
Back to top